Skip to main content
K Pharma,Inc. logo

K Pharma,Inc. — Investor Relations & Filings

Ticker · 4896 ISIN · JP3280900006 T Manufacturing
Open in API
Filings indexed 23 across all filing types
Latest filing 2024-03-28 Governance Information
Country JP Japan
Listing T 4896

About K Pharma,Inc.

https://en.kpharma.co.jp/

K Pharma, Inc. is a biotechnology company that specializes in medical treatments derived from induced pluripotent stem (iPS) cell technology. The company's operations are centered on two key areas: iPS drug discovery and regenerative medicine. Its research, development, manufacturing, and sales activities are primarily focused on the central nervous system (CNS), with a specific emphasis on nerve regeneration. K Pharma develops therapies for conditions such as spinal cord injuries and cerebral infarctions by utilizing disease-specific iPS cells. The company was established as a spin-off venture from the Keio University School of Medicine to commercialize advanced academic research.

Recent filings

Filing Released Lang Actions
内部統制報告書－第7期(2023/01/01－2023/12/31)
Governance Information Classification · 1% confidence The document is titled "内部統制報告書" (Internal Control Report) in the header section. It explicitly mentions compliance with the Financial Instruments and Exchange Act (金融商品取引法第24条の４の４第１項) and details the scope, criteria, and procedures for evaluating internal controls over financial reporting (財務報告に係る内部統制). This content directly corresponds to the requirements for an Audit Report or specific regulatory compliance documentation related to internal controls, which aligns best with the 'Audit Report / Information' category (AR), as it is a formal report on internal control effectiveness, distinct from a full Annual Report (10-K) or a simple Earnings Release (ER).
2024-03-28 Japanese
有価証券報告書－第7期(2023/01/01－2023/12/31)
Annual Report Classification · 1% confidence The document is a Japanese '有価証券報告書' (Yuuka Shouken Houkokusho), which translates to 'Annual Securities Report'. This is the standard Japanese regulatory filing equivalent to the US 10-K, containing comprehensive financial statements, business overview, and management analysis for the fiscal year ending December 31, 2023. It is filed with the Kanto Local Finance Bureau under the Financial Instruments and Exchange Act. FY 2023
2024-03-28 Japanese
確認書
Report Publication Announcement Classification · 1% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act in Japan. It specifically confirms the accuracy of the contents of a Quarterly Report (Shihanki Hokokusho) for the third quarter of the 7th fiscal period. Since this is a regulatory filing confirming the accuracy of a report rather than the report itself, and it does not fit into the specific categories like 10-K or IR, it falls under the general regulatory filing category.
2023-11-13 Japanese
四半期報告書－第7期第3四半期(2023/07/01－2023/09/30)
Interim / Quarterly Report Classification · 1% confidence The document is a Japanese 'Quarterly Report' (四半期報告書) filed with the Kanto Local Finance Bureau under the Financial Instruments and Exchange Act. It contains detailed financial statements (balance sheet, income statement) for the third quarter of the fiscal year ending 2023. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2023
2023-11-13 Japanese
臨時報告書
Major Shareholding Notification Classification · 1% confidence The document is a 'Rinji Hokokusho' (Extraordinary Report) filed with the Kanto Local Finance Bureau. The content explicitly states that the reason for the filing is a change in a major shareholder ('主要株主に変動がありました'). This type of regulatory filing in Japan, which reports significant changes in shareholding thresholds or major ownership, falls under the category of Major Shareholding Notification (MRQ).
2023-10-17 Japanese
訂正有価証券届出書（新規公開時）
Capital/Financing Update Classification · 1% confidence The document is a 'Yuka Shoken Todokesho' (Securities Registration Statement) filed with the Kanto Local Finance Bureau in Japan. It details a public offering of shares (IPO) for K Pharma, Inc., including the offering price, underwriting details, and use of proceeds. This type of regulatory filing for a new share issuance and listing on the Tokyo Stock Exchange falls under the 'Share Issue/Capital Change' category.
2023-10-06 Japanese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.